Future Financial Wealth Managment LLC Has $1.32 Million Position in Eli Lilly and Company $LLY

Future Financial Wealth Managment LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,698 shares of the company’s stock after buying an additional 120 shares during the period. Eli Lilly and Company comprises about 0.9% of Future Financial Wealth Managment LLC’s investment portfolio, making the stock its 23rd biggest holding. Future Financial Wealth Managment LLC’s holdings in Eli Lilly and Company were worth $1,324,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of LLY. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Matrix Trust Co lifted its stake in Eli Lilly and Company by 25.9% in the first quarter. Matrix Trust Co now owns 267 shares of the company’s stock valued at $221,000 after acquiring an additional 55 shares during the last quarter. Beacon Financial Group lifted its stake in Eli Lilly and Company by 4.2% in the first quarter. Beacon Financial Group now owns 446 shares of the company’s stock valued at $368,000 after acquiring an additional 18 shares during the last quarter. Finally, Charles Schwab Trust Co lifted its stake in Eli Lilly and Company by 41.1% in the first quarter. Charles Schwab Trust Co now owns 453 shares of the company’s stock valued at $374,000 after acquiring an additional 132 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their target price for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Finally, JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $933.39.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 2.5%

Shares of LLY stock opened at $840.46 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The firm has a market cap of $795.47 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The stock has a 50 day moving average of $734.60 and a 200-day moving average of $766.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.